Obama administration expressed growing fears that Ebola will become a global pandemic affecting the USA as it has affected West Africa where it left more than 4,500 dead in six months. For this reason the president ordered several advanced laboratories carry out to large-scale production of miraculous serum ZMapp, the stocks of which had been depleted, and which has so far been the most effective on the infected, although it is still in the experimental stage.
ZMapp was given in July to the American missionaries, Dr. Kent Brantly and Nurse Nancy Writebol, who healed after contracting the virus in Liberia and whose lives had fallen short of being gave up on.
Dr. Kent Brantly, 33, and the aid worker Nancy Writebol, 59, were the first patients ever to receive the experimental treatment with the vaccine ZMapp. Back in August, when the two walked out of the hospital in Atlanta after the weeks in isolation unit, Dr. Ribner who was in charge of the treatment given to Dr. Brantly and Mrs. Writebol, said that he and his colleagues were not certain about the role of the vaccine in the healing of his patients. This certainty was gained later with the follow-ups that continued during the next months.
The patients treated with ZMapp were confirmed as immune to this particulat strain of Ebola, but there is still no data on whether they are immune to other strains related to this virus, says NBC News.
Among the involved laboratories from the Biomedical Advanced Research and Development Authority (BARDA), which will coordinate the research and control the developments, Texas A & M Health Science Center and the Centers for Innovation in Advanced Development and Manufacturing will work with the British pharmaceutical giant GlaxoSmithKline to develop a vaccine against the virus.
To these are added the Emergent Biosolutions to Baltimore and another facility in Holly Springs North Carolina, coordinated by the Swiss giant Novartis AG.
The appointment for a test is near: on November 10 BARDA will select one or more laboratories to begin mass production of ZMapp, developed by Mapp Biopharmaceutical of San Diego in California.